EP. 1: R/R Follicular Lymphoma: Patient Prognosis
Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.
EP. 2: R/R Follicular Lymphoma: Second-line Treatment Selection
Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.
EP. 3: Role of Rebiopsy in R/R Follicular Lymphoma
The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.
EP. 4: MRD Testing in R/R Follicular Lymphoma
Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.
EP. 5: Transplantation for R/R Follicular Lymphoma
The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.
EP. 6: R/R Follicular Lymphoma: Third-Line Treatment Options
Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.
EP. 7: PI3K Inhibitors for R/R Follicular Lymphoma
Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.
EP. 8: R2 Regimen for R/R Follicular Lymphoma
An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.
EP. 9: Tazemetostat for R/R Follicular Lymphoma
Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.
EP. 10: EZH2 Inhibition in R/R FL: Safety & Efficacy Data
Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.
EP. 11: R/R Follicular Lymphoma: Testing for EZH2
Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.
EP. 12: Case Discussion: 68-Year-Old With R/R Follicular Lymphoma
A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
EP. 13: Emerging Therapies for R/R Follicular Lymphoma
An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.
EP. 14: Treating Follicular Lymphoma With Early Progression
Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).
EP. 15: ZUMA-5 in R/R Follicular Lymphoma
Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.
EP. 16: CAR T-Cell Therapy for R/R Follicular Lymphoma
Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.
EP. 18: Novel Therapies for R/R Follicular Lymphoma
A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.